DelMar Collaborates with PRA Health Sciences

DelMar Pharmaceuticals, a biopharmaceutical company focused on developing new cancer therapies, has formed an agreement with PRA Health Sciences, a contract research organization (CRO), to conduct the company's Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).

"We have been working with PRA for quite some time in preparing for VAL-083's Phase 3 study in GBM," said Jeffrey Bacha, chairman and chief executive officer, DelMar Pharmaceuticals. "Given our recent $9 million financing, we have the resources to facilitate the initiation of our pivotal Phase 3 study of VAL-083 as a single agent treatment for GBM patients who have failed both temozolomide (Temodar) and bevacizumab (Avastin), for whom there is no currently approved therapy. We are delighted to formally engage with a CRO of the caliber and reputation of PRA to run this Phase 3 study of a treatment for a cancer indication in which there is an utmost medical need in the eyes of oncologists and the FDA."

PRA Health Sciences is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries.